The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1523
Issue 1523
Abaloparatide (Tymlos) for Postmenopausal Osteoporosis; Ocrelizumab (Ocrevus) for MS; Acetylcysteine (Cetylev) for Acetaminophen Overdose; Obalon Balloon System - Another Gastric Balloon for Weight Loss; Riboflavin (Photrexa) and Ultraviolet Light for Progressive Keratoconus; Comparison Table: Drugs for Postmenopausal Osteoporosis (online only)
The full issue is available to subscribers Subscriber Login   
Abaloparatide (Tymlos) for Postmenopausal Osteoporosis

The FDA has approved abaloparatide (Tymlos – Radius Health), a synthetic analog of human parathyroid hormone related peptide, for treatment of postmenopausal women with osteoporosis who are at high risk for fracture. Abaloparatide is the second parathyroid hormone receptor agonist to be approved for this indication; teriparatide (Forteo – Lilly), a recombinant parathyroid hormone analog, was the first. They are the only drugs approved for treatment of osteoporosis that stimulate bone formation. Other drugs used for this indication inhibit bone resorption.1

ACTIVITY — Given continuously, human parathyroid hormone has a catabolic effect on bone, but when it is given once daily in low doses, bone formation predominates. Abaloparatide, like teriparatide, increases bone mineral density (BMD) and bone formation markers. ... more       Show References Hide References

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this issue:
Title: Issue 1523
Select version:
 Downloadable, electronic issue - $35
 Postal, hardcopy issue - $35